Comparative Pharmacology
Head-to-head clinical analysis: CONRAY versus CONRAY 325.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY versus CONRAY 325.
CONRAY vs CONRAY 325
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is an ionic, high-osmolality radiopaque contrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during radiographic procedures.
Iodinated contrast agent that attenuates X-rays by blocking photons, allowing visualization of blood vessels and tissues.
Intravenous: 20-60 mL for CT enhancement; intra-arterial: 5-80 mL per injection; concentration 282 mgI/mL (iothalamate meglumine). Dose based on procedure, body weight, and renal function.
Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum total dose 250 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. May be prolonged in renal impairment.
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% biliary or fecal.
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent